Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Diane L. Pickering is active.

Publication


Featured researches published by Diane L. Pickering.


American Journal of Pathology | 2001

Fusion of the ALK Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic Tumor

Julia A. Bridge; Masahiko Kanamori; Zhigui Ma; Diane L. Pickering; D. Ashley Hill; William M. Lydiatt; Man Yee Lui; Gisele W.B. Colleoni; Cristina R. Antonescu; Marc Ladanyi; Stephan W. Morris

Inflammatory myofibroblastic tumor (IMT) is a rare, but distinctive mesenchymal neoplasm composed of fascicles of bland myofibroblasts admixed with a prominent inflammatory component. Genetic studies of IMTs have demonstrated chromosomal abnormalities of 2p23 and rearrangement of the anaplastic lymphoma kinase (ALK) gene locus. In a subset of IMTs, the ALK C-terminal kinase domain is fused with a tropomyosin N-terminal coiled-coil domain. In the current study, fusion of ALK with the clathrin heavy chain (CTLC) gene localized to 17q23 was detected in two cases of IMT. One of these cases exhibited a 2;17 translocation in addition to other karyotypic anomalies [46,XX,t(2;17)(p23;q23),add(16)(q24)].


Genetics in Medicine | 2011

An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities

Erin B. Kaminsky; Vineith Kaul; Justin Paschall; Deanna M. Church; Brian Bunke; Dawn Kunig; Daniel Moreno-De-Luca; Andres Moreno-De-Luca; Jennifer G. Mulle; Stephen T. Warren; Gabriele Richard; John Compton; Amy E. Fuller; Troy J. Gliem; Shuwen Huang; Morag N. Collinson; Sarah J. Beal; Todd Ackley; Diane L. Pickering; Denae M. Golden; Emily Aston; Heidi Whitby; Shashirekha Shetty; Michael R. Rossi; M. Katharine Rudd; Sarah T. South; Arthur R. Brothman; Warren G. Sanger; Ramaswamy K. Iyer; John A. Crolla

Purpose: Copy number variants have emerged as a major cause of human disease such as autism and intellectual disabilities. Because copy number variants are common in normal individuals, determining the functional and clinical significance of rare copy number variants in patients remains challenging. The adoption of whole-genome chromosomal microarray analysis as a first-tier diagnostic test for individuals with unexplained developmental disabilities provides a unique opportunity to obtain large copy number variant datasets generated through routine patient care.Methods: A consortium of diagnostic laboratories was established (the International Standards for Cytogenomic Arrays consortium) to share copy number variant and phenotypic data in a central, public database. We present the largest copy number variant case-control study to date comprising 15,749 International Standards for Cytogenomic Arrays cases and 10,118 published controls, focusing our initial analysis on recurrent deletions and duplications involving 14 copy number variant regions.Results: Compared with controls, 14 deletions and seven duplications were significantly overrepresented in cases, providing a clinical diagnosis as pathogenic.Conclusion: Given the rapid expansion of clinical chromosomal microarray analysis testing, very large datasets will be available to determine the functional significance of increasingly rare copy number variants. This data will provide an evidence-based guide to clinicians across many disciplines involved in the diagnosis, management, and care of these patients and their families.


American Journal of Pathology | 2004

BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

Javeed Iqbal; Warren G. Sanger; Douglas E. Horsman; Andreas Rosenwald; Diane L. Pickering; Bhavana J. Dave; Sandeep S. Dave; Li Xiao; Kajia Cao; Quiming Zhu; Simon Sherman; Christine P. Hans; Dennis D. Weisenburger; Timothy C. Greiner; Randy D. Gascoyne; German Ott; H. Konrad Muller-Hermelink; Jan Delabie; Rita M. Braziel; Elaine S. Jaffe; Elias Campo; James C. Lynch; Joseph M. Connors; Julie M. Vose; James O. Armitage; Thomas M. Grogan; Louis M. Staudt; Wing C. Chan

Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed prognostically important subgroups: germinal center B-cell-like (GCB) DLBCL, activated B cell-like (ABC) DLBCL, and primary mediastinal large B-cell lymphoma. The t(14;18)(q32;q21) has been reported previously to define a unique subset within the GCB-DLBCL. We evaluated for the translocation in 141 cases of DLBCL that were successfully gene expression profiled. Using a dual-probe fluorescence in situ hybridization assay, we detected the t(14;18) in 17% of DLBCLs and in 34% of the GCB subgroup which contained the vast majority of positive cases. In addition, 12 t(14;18)-positive cases detected by polymerase chain reaction assays on additional samples were added to the fluorescence in situ hybridization-positive cases for subsequent analysis. Immunohistochemical data indicated that BCL2, BCL6, and CD10 protein were preferentially expressed in the t(14;18)-positive cases as compared to t(14;18)-negative cases. Within the GCB subgroup, the expression of BCL2 and CD10, but not BCL6, differed significantly between cases with or without the t(14;18): 88% versus 24% for BCL2 and 72% versus 32% for CD10, respectively. In the GCB-DLBCL subgroup, a heterogeneous group of genes is overexpressed in the t(14;18)-positive subset, among which BCL2 is a significant discriminator. Interestingly, the t(14;18)-negative subset is dominated by overexpression of cell cycle-associated genes, indicating that these tumors are significantly more proliferative, suggesting distinctive pathogenetic mechanisms. However, despite this higher proliferative activity, there was no significant difference in overall or failure-free survival between the t(14;18)-positive and -negative subsets within the GCB subgroup.


American Journal of Human Genetics | 2010

Deletion 17q12 Is a Recurrent Copy Number Variant that Confers High Risk of Autism and Schizophrenia

Daniel Moreno-De-Luca; Jennifer G. Mulle; Erin B. Kaminsky; Stephan J. Sanders; Scott M. Myers; Margaret P Adam; Amy T. Pakula; Nancy J. Eisenhauer; Kim Uhas; LuAnn Weik; Lisa Guy; Melanie Care; Chantal Morel; Charlotte Boni; Bonnie Anne Salbert; Ashadeep Chandrareddy; Laurie A. Demmer; Eva W.C. Chow; Urvashi Surti; Swaroop Aradhya; Diane L. Pickering; Denae M. Golden; Warren G. Sanger; Emily Aston; Arthur R. Brothman; Troy J. Gliem; Erik C. Thorland; Todd Ackley; Ram Iyer; Shuwen Huang

Autism spectrum disorders (ASD) and schizophrenia are neurodevelopmental disorders for which recent evidence indicates an important etiologic role for rare copy number variants (CNVs) and suggests common genetic mechanisms. We performed cytogenomic array analysis in a discovery sample of patients with neurodevelopmental disorders referred for clinical testing. We detected a recurrent 1.4 Mb deletion at 17q12, which harbors HNF1B, the gene responsible for renal cysts and diabetes syndrome (RCAD), in 18/15,749 patients, including several with ASD, but 0/4,519 controls. We identified additional shared phenotypic features among nine patients available for clinical assessment, including macrocephaly, characteristic facial features, renal anomalies, and neurocognitive impairments. In a large follow-up sample, the same deletion was identified in 2/1,182 ASD/neurocognitive impairment and in 4/6,340 schizophrenia patients, but in 0/47,929 controls (corrected p = 7.37 × 10⁻⁵). These data demonstrate that deletion 17q12 is a recurrent, pathogenic CNV that confers a very high risk for ASD and schizophrenia and show that one or more of the 15 genes in the deleted interval is dosage sensitive and essential for normal brain development and function. In addition, the phenotypic features of patients with this CNV are consistent with a contiguous gene syndrome that extends beyond RCAD, which is caused by HNF1B mutations only.


Leukemia | 2007

Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.

Javeed Iqbal; Timothy C. Greiner; K. Patel; Bhavana J. Dave; Lynette M. Smith; J. Ji; George E. Wright; Warren G. Sanger; Diane L. Pickering; Smrati Jain; Douglas E. Horsman; Yulei Shen; Kai Fu; Dennis D. Weisenburger; C. P. Hans; Elias Campo; Randy D. Gascoyne; Andreas Rosenwald; Elaine S. Jaffe; Jan Delabie; Lisa M. Rimsza; German Ott; H. K. Müller-Hermelink; Joseph M. Connors; Julie M. Vose; Timothy W. McKeithan; Louis M. Staudt; Wing-Chung Chan

Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed biologically and prognostically distinct subgroups: germinal center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal (PM) DLBCL. The BCL6 gene is often translocated and/or mutated in DLBCL. Therefore, we examined the BCL6 molecular alterations in these DLBCL subgroups, and their impact on BCL6 expression and BCL6 target gene repression. BCL6 translocations at the major breakpoint region (MBR) were detected in 25 (18.8%) of 133 DLBCL cases, with a higher frequency in the PM (33%) and ABC (24%) subgroups than in the GCB (10%) subgroup. Translocations at the alternative breakpoint region (ABR) were detected in five (6.4%) of 78 DLBCL cases, with three cases in ABC and one case each in the GCB and the unclassifiable subgroups. The translocated cases involved IgH and non-IgH partners in about equal frequency and were not associated with different levels of BCL6 mRNA and protein expression. BCL6 mutations were detected in 61% of DLBCL cases, with a significantly higher frequency in the GCB and PM subgroups (>70%) than in the ABC subgroup (44%). Exon-1 mutations were mostly observed in the GCB subgroup. The repression of known BCL6 target genes correlated with the level of BCL6 mRNA and protein expression in GCB and ABC subgroups but not with BCL6 translocation and intronic mutations. No clear inverse correlation between BCL6 expression and p53 expression was observed. Patients with higher BCL6 mRNA or protein expression had a significantly better overall survival. The biological role of BCL6 in translocated cases where repression of known target genes is not demonstrated is intriguing and warrants further investigation.


The American Journal of Surgical Pathology | 2001

Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma.

Matthew R. Mendlick; Marilu Nelson; Diane L. Pickering; Sonny L. Johansson; Thomas A. Seemayer; James R. Neff; Gerardo Vergara; Howard G. Rosenthal; Julia A. Bridge

The cytogenetic findings for two epithelioid hemangioendotheliomas are reported. An identical chromosomal translocation involving chromosomes 1 and 3 [t(1;3)(p36.3;q25)] was detected in both cases of epithelioid hemangioendothelioma, possibly representing a characteristic rearrangement for this histopathologic entity. The presence of clonal karyotypic abnormalities supports a neoplastic origin for the epithelioid variant of hemangioendothelioma. Identification of the 1;3 translocation may be useful diagnostically. Should additional studies confirm these data, this could lead to the identification of the gene(s) central to this neoplastic process.


Genetics in Medicine | 2008

Array-based comparative genomic hybridization analysis of 1176 consecutive clinical genetics investigations

Diane L. Pickering; James D. Eudy; Ann Haskins Olney; Bhavana J. Dave; Denae M. Golden; Jadd M. Stevens; Warren G. Sanger

Purpose: Cytogenetic investigations are useful for etiologic determinations of mental retardation, developmental delay, multiple congenital anomalies, and pregnancy complications; however, the causes remain elusive in a majority of cases despite high-resolution cytogenetic studies and multiple fluorescence in situ hybridization examinations. Array-based comparative genomic hybridization has the ability to examine the genome at a higher resolution and may yield an increased detection of genetic abnormalities. The purpose of this study was to assess the use of array-based comparative genomic hybridization in a clinical genetics setting.Methods: DNA from 1176 patients was analyzed using a bacterial artificial chromosome array-based comparative genomic hybridization platform. All abnormal cases were confirmed by fluorescence in situ hybridization and parental studies were completed when possible.Results: Of the 1176 patients included in this survey, 163 showed a genomic imbalance identified by array-based comparative genomic hybridization. Of these 163 cases, 116 had a clinically relevant genetic abnormality. A total of 9.8% (116 of 1176 cases) were determined to exhibit a causative genomic imbalance. Twenty-five of the 116 abnormal cases had a previously identified cytogenetic abnormality yielding an increased detection rate of 7.9% (91 of 1146) in cases with normal or no cytogenetics.Conclusion: Array-based comparative genomic hybridization increases the overall abnormality detection rate, thus improving the diagnostic potential of clinical cytogenetics investigations.


British Journal of Haematology | 2005

Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: A genetic and pathological correlation

Sherrie L. Perkins; Diane L. Pickering; Eric J. Lowe; David Zwick; Minnie Abromowitch; Ginny Davenport; Mitchell S. Cairo; Warren G. Sanger

Anaplastic large cell lymphoma (ALCL) comprises 10–15% of childhood non‐Hodgkin lymphomas (NHL). Systemic ALCL is highly associated with anaplastic lymphoma kinase (ALK) gene translocations with over‐expression of ALK protein. We studied ALK rearrangements using fluorescence in situ hybridisation (FISH) and ALK immunohistochemical staining in 43 paediatric systemic ALCLs. FISH (performed on 35 cases) identified a translocation in 29 cases (83%). Immunohistochemistry identified ALK over‐expression in 42/43 cases (97%) with the single ALK‐negative case demonstrating an ALK rearrangement by FISH, indicating 100% incidence of ALK translocations.


Cancer Genetics and Cytogenetics | 1999

Deletion of Cell Division Cycle 2-Like 1 Gene Locus on 1p36 in Non-Hodgkin Lymphoma

Bhavana J. Dave; Diane L. Pickering; Michelle M. Hess; Dennis D. Weisenburger; James O. Armitage; Warren G. Sanger

Our laboratories have documented a significantly high occurrence of chromosome 1p36 rearrangements in non-Hodgkin lymphoma (NHL). The cell division cycle 2-like 1(CDC2L1) (also known as TP58 or PITSLRE) gene, a protein kinase implicated in apoptotic signaling, is located at the very distal region of chromosome 1p36 and is likely to be disrupted by structural rearrangements involving 1p36. To determine the molecular consequences of the recurrent involvement of the 1p36 region, we examined metaphases containing 1p36 abnormalities from 31 specimens derived from 26 patients for the possible deletion of CDC2L1 by fluorescence in situ hybridization (FISH) using the TP58clk-1 DNA probe. Twenty-three cases exhibited the loss of CDC2L1 from the abnormal chromosome 1. In 2 of 26 cases, the gene locus was translocated to the partner chromosome, and in four specimens, all derived from one case, CDC2L1 was not deleted. This pilot investigation suggests that 1p36 rearrangements, and consequently the loss of the CDC2L1 gene locus, is important in NHL. This work also opens avenues for further molecular studies and prognostic correlations.


Cancer Genetics and Cytogenetics | 1998

Involvement of 3q21 in Nodular Fasciitis

Vines Weibolt; Cary J Buresh; Cory A. Roberts; Ron F. Suijkerbuijk; Diane L. Pickering; James R. Neff; Julia A. Bridge

Cytogenetic data on nodular fasciitis are sparse. We present a case of this lesion and discuss our results in view of previously reported findings in nodular fasciitis and other benign mesenchymal lesions.

Collaboration


Dive into the Diane L. Pickering's collaboration.

Top Co-Authors

Avatar

Warren G. Sanger

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Bhavana J. Dave

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Dennis D. Weisenburger

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ann Haskins Olney

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

James O. Armitage

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Michelle M. Hess

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Denae M. Golden

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jadd M. Stevens

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Julia A. Bridge

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

James R. Neff

University of Nebraska Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge